New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO) -February 01, 2024 at 01:06 am EST

– Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision –


– Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three...

Related Keywords

Paris ,France General ,France ,California ,United States ,Florida ,South San Francisco ,Levi Garraway ,Ramin Tadayoni ,Genentech ,Drug Administration ,Roche Group ,Clinical Development Program ,Bascom Palmer Eye Institute ,Global Product Development ,Global Product ,Paris Cit ,Retinal Vein Occlusion ,Clinical Development ,Important Safety Information ,Vabysmo Prescribing Information ,Markets ,